Lundbeck Showcases Bexicaserin at the AES Annual Meeting
Longboard Pharmaceuticals, now fully integrated into Lundbeck, is making headlines at the American Epilepsy Society (AES) Annual Meeting with multiple scientific presentations. The focus is on bexicaserin, an innovative compound poised to change the treatment landscape for those suffering from Developmental and Epileptic Encephalopathies (DEEs).
The Significance of Bexicaserin
Bexicaserin, a highly selective investigational treatment, is designed to address the pressing needs of patients facing severe forms of epilepsy. Its potential to relieve symptoms associated with DEEs marks a significant advancement for Lundbeck and the broader epilepsy community.
Recent Developments and Presentations
Lundbeck's acquisition of Longboard Pharmaceuticals signifies a strategic enhancement to its pipeline. The PACIFIC Study, a phase II trial conducted by Longboard, has set the stage for promising new avenues in epilepsy treatment. During the AES Annual Meeting, Lundbeck plans to present a series of posters detailing their findings and innovations with bexicaserin.
Engagement at AES
The AES platform serves as an exceptional venue for Lundbeck to present its findings and engage with thought leaders in the epilepsy field. Johan Luthman, Lundbeck’s EVP and Head of Research & Development, expressed optimism regarding the discussions around bexicaserin’s clinical potential, highlighting its designation as a Breakthrough Therapy by the FDA.
Data Presentation Highlights
Several key presentations are planned for the AES meeting:
- Saturday, December 7, 2024
- Title: Bexicaserin's Safety, Tolerability and Efficacy in a Cohort of Participants with DEEs: Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension (Poster number: 1.509)
- Title: Additional Efficacy Analyses of the Bexicaserin PACIFIC Study: Responder Rates, Number Needed to Treat, and Seizure-Free Days (Poster number: 1.402)
- Title: Bexicaserin Reduces Seizures and Respiratory Arrest in a Mouse Model of SUDEP (Poster number: 1.505)
- Title: Bexicaserin Exhibits High Selectivity for the 5-HT2C Receptor with Low Off-Target Activity (Poster number: 1.506)
- Title: Preliminary Results from a Controlled Study of Sleep Disruption in Caregivers of Individuals with Lennox-Gastaut Syndrome (Poster number: 1.531)
- Monday, December 9, 2024
- Title: Bexicaserin Demonstrates Similar Reduction of Countable Motor Seizures in Adolescents and Adults with DEEs: Analysis of the Phase 1b/2a PACIFIC Study (Poster number: 3.399)
- Title: Bexicaserin has Negligible Drug-Drug Interaction Potential with Frequently Used Antiseizure Medications (Poster number: 3.400)
- Title: Cocktail Approach for Assessment of Bexicaserin as a Perpetrator on Pharmacokinetics of Renal, Hepatic, Transporters, and CYP/UGT Enzymes (Poster number: 3.401)
- Scientific Exhibit: Bexicaserin: A Novel Serotonergic Medication for Seizures Associated with DEEs (Location: Room 404 AB, Los Angeles Convention Center)
About Bexicaserin
Bexicaserin (LP352) is an oral medication acting as a 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, showing promise in alleviating seizures related to DEEs. Currently under a global Phase III clinical program, this investigational treatment could be a game-changer for those aged two and older.
About H. Lundbeck A/S
Lundbeck is dedicated to advancing brain health through pioneering neuroscience research and development. With a legacy spanning over 70 years, the company's mission is to improve healthcare outcomes for individuals afflicted with neurological and psychiatric disorders.
Commitment to Improving Lives
Not only does Lundbeck develop transformative medicines, but the company also aims to reduce stigma surrounding brain disorders while enhancing health equity. Their portfolio encompasses various treatments, establishing them as leaders in neuro-specialty and neuro-rare areas, while also focusing on enriching the lives of patients and families.
Frequently Asked Questions
What is Bexicaserin?
Bexicaserin is an investigational treatment aimed at managing seizures associated with Developmental and Epileptic Encephalopathies.
What designations has Bexicaserin received?
Bexicaserin has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation by the FDA.
When is the AES Annual Meeting?
The AES Annual Meeting takes place in December 2024, with various presentations scheduled on the 7th and 9th.
What is the significance of the PACIFIC Study?
The PACIFIC Study is a critical phase II program that establishes the foundation for bexicaserin's potential effectiveness in treating DEEs.
How does Lundbeck contribute to the epilepsy community?
Lundbeck is committed to advancing treatments for severe epilepsy and engaging with healthcare professionals and advocacy groups to raise awareness and improve patient care.
